News
VIRX
0.0080
NaN%
--
Weekly Report: what happened at VIRX last week (0707-0711)?
Weekly Report · 07/14/2025 09:25
Weekly Report: what happened at VIRX last week (0630-0704)?
Weekly Report · 07/07/2025 09:23
Weekly Report: what happened at VIRX last week (0623-0627)?
Weekly Report · 06/30/2025 09:24
Weekly Report: what happened at VIRX last week (0616-0620)?
Weekly Report · 06/23/2025 09:23
Weekly Report: what happened at VIRX last week (0609-0613)?
Weekly Report · 06/16/2025 09:24
Weekly Report: what happened at VIRX last week (0602-0606)?
Weekly Report · 06/09/2025 09:24
Weekly Report: what happened at VIRX last week (0526-0530)?
Weekly Report · 06/02/2025 09:26
Weekly Report: what happened at VIRX last week (0519-0523)?
Weekly Report · 05/26/2025 09:26
Weekly Report: what happened at VIRX last week (0512-0516)?
Weekly Report · 05/19/2025 09:24
Weekly Report: what happened at VIRX last week (0505-0509)?
Weekly Report · 05/12/2025 09:25
Weekly Report: what happened at VIRX last week (0428-0502)?
Weekly Report · 05/05/2025 09:24
Weekly Report: what happened at VIRX last week (0421-0425)?
Weekly Report · 04/28/2025 09:27
Weekly Report: what happened at VIRX last week (0414-0418)?
Weekly Report · 04/21/2025 09:27
Weekly Report: what happened at VIRX last week (0407-0411)?
Weekly Report · 04/14/2025 09:25
More
Webull provides a variety of real-time VIRX stock news. You can receive the latest news about Viracta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIRX
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.